Inactive Instrument

InspireMD Inc Stock NYSE

US45779A3095

Medical Equipment, Supplies & Distribution

End-of-day quote NYSE
- ^USD	-

08-17	InspireMD, Inc., Q2 2026 Earnings Call, Aug 17, 2026
08-14	InspireMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Last Transcript: InspireMD Inc

InspireMD, Inc., Q2 2026 Earnings Call, Aug 17, 2026

08-17

More transcripts

Analysts' recommendations: InspireMD Inc

23-06-12	Piper Sandler Initiates InspireMD at Overweight With $3 Price Target	MT
23-05-17	Alliance Global Adjusts Price Target on InspireMD to $4.75 From $5.15, Maintains Buy Rating	MT

More recommendations

Managers and Directors: InspireMD Inc

Manager	Title	Age	Since
Marvin Slosman CEO	Chief Executive Officer	62	2019-12-31
Michael Lawless DFI	Director of Finance/CFO	58	2025-06-24
Shany Barel CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Stuka CHM	Chairman	71	2017-06-01
Michael Berman BRD	Director/Board Member	68	2013-02-06
Marvin Slosman BRD	Director/Board Member	62	2019-12-31

More insiders

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	22.31M 19.93M 18.59M 16.89M 31.78M 2.16B 32.09M 223M 87.3M 1.1B 83.78M 81.96M 3.53B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	22.31M 19.93M 18.59M 16.89M 31.78M 2.16B 32.09M 223M 87.3M 1.1B 83.78M 81.96M 3.53B	EV / Sales 2026 *	2.28x	EV / Sales 2027 *	1.11x
Free-Float	80.03%	Yield 2026 *	-	Yield 2027 *	-

08-17	InspireMD, Inc., Q2 2026 Earnings Call, Aug 17, 2026
08-14	InspireMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	InspireMD, Inc. Appoints Kathleen Kennedy as Senior Vice President of Global Sales and Marketing	CI
07-29	InspireMD, Inc. Announces Elimination of Shane Gleason as Chief Commercial Officer, Effective July 31, 2026	CI
07-24	InspireMD Receives Nasdaq Minimum Bid Price Warning	MT
07-02	InspireMD, Inc. Announces Resignation of Raymond W. Cohen from Board and Committees, Effective July 1, 2026	CI
06-29	InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell 3000E Growth Benchmark	CI
06-28	InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index	CI
06-19	InspireMD, Inc. Announces Recalling Action on CGuard Prime Carotid Stent System 135Cm, 10Mmx30mm	CI
06-19	InspireMD, Inc. Announces Recalling Action for CGuard Prime Carotid Stent System 135cm, 10mmx40mm	CI
06-19	Inspiremd Inc Announces Recalling Action on Cguard Prime Carotid Stent System 135cm, 9mx30mm	CI
06-19	InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm	CI
06-19	InspireMD Inc Announces Recalling Action For CGuard Prime Carotid Stent System 135cm, 8mmx40mm	CI

09-21	InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million	AQ
09-04	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
09-03	InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-17	InspireMD Reports Second Quarter 2026 Financial Results	AQ
08-10	InspireMD to Announce Second Quarter 2026 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABBOTT LABORATORIES	-0.24%	+1.86%	-26.65%	+1.66%	170B
MEDTRONIC PLC	+2.62%	+1.52%	-10.34%	+15.28%	112B
STRYKER CORPORATION	+0.57%	+1.47%	-26.20%	+4.18%	106B
ESSILORLUXOTTICA	+2.06%	+2.21%	-47.50%	-10.62%	73.6B
CENCORA, INC.	+1.29%	+3.73%	+3.46%	+74.79%	61.32B
HOYA CORPORATION	+0.12%	+3.62%	+12.66%	+65.87%	52.89B
BECTON, DICKINSON AND COMPANY	+1.44%	+2.63%	-5.76%	-30.36%	49.78B
IDEXX LABORATORIES, INC.	+1.28%	-0.89%	-18.54%	+15.06%	40.43B
DEXCOM, INC.	+0.13%	-2.11%	+24.54%	+1.43%	31.85B
Average	+0.43%	+1.29%	-10.48%	+15.25%	77.64B
Weighted average by Cap.	+0.36%	+1.54%	-16.25%	+12.70%

	2026 *	2027 *
Net sales	9.8M 8.75M 8.16M 7.42M 13.95M 949M 14.09M 98.01M 38.33M 482M 36.79M 35.99M 1.55B	20.13M 17.98M 16.77M 15.23M 28.67M 1.95B 28.95M 201M 78.76M 991M 75.59M 73.95M 3.19B
Net income	-	-
Net Debt	-	-

InspireMD Inc Stock NYSE

Stocks

US45779A3095

Medical Equipment, Supplies & Distribution

Valuation: InspireMD Inc

Latest news: InspireMD Inc

Last Transcript: InspireMD Inc

Analysts' recommendations: InspireMD Inc

Press Releases: InspireMD Inc

Managers and Directors: InspireMD Inc

Medical Devices & Implants

Financials

Company Profile